🇺🇸 DTPa-IPV/Hib vaccine in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 19

Most-reported reactions

1. Hypersensitivity — 3 reports (15.79%)
2. Anaphylactic Reaction — 2 reports (10.53%)
3. Decreased Appetite — 2 reports (10.53%)
4. Foetal Exposure During Pregnancy — 2 reports (10.53%)
5. Pyrexia — 2 reports (10.53%)
6. Somnolence — 2 reports (10.53%)
7. Urticaria — 2 reports (10.53%)
8. Vomiting — 2 reports (10.53%)
9. Abdominal Pain — 1 report (5.26%)
10. Abdominal Pain Upper — 1 report (5.26%)

Source database →

Frequently asked questions

Is DTPa-IPV/Hib vaccine approved in United States?

DTPa-IPV/Hib vaccine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for DTPa-IPV/Hib vaccine in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.